Showing results (41-50 of 405) with videos related to
Sort By:
Pageof 41
Current Treatment Options in Neurology|May 24, 2021
Early Aggressive Treatment Approaches for Multiple SclerosisAlexandra Simpson, Ellen M Mowry, Scott D NewsomeInternational Journal of MS Care|September 18, 2023
Serum Sickness/Serum Sickness-like Reactions Following Ocrelizumab Infusion in 2 Patients With Multiple SclerosisNicole Bou Rjeily, Bardia Nourbakhsh, Ellen M MowryMultiple Sclerosis and Related Disorders|October 26, 2022
Benefits of early treatment with natalizumab: a real-world studyDaniel Ontaneda, Ellen M Mowry, Scott D Newsome, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 6, 2024
How to avoid missing a diagnosis of neuromyelitis optica spectrum disorderEdgar Carnero Contentti, Dalia Rotstein, Darin T Okuda, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 4, 2025
Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysisMahsa Ghajarzadeh, Mohsen Rastkar, Ellen M Mowry, et al.CNS Drugs|September 27, 2015
Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisAdnan M Subei, Daniel OntanedaNeurodegenerative Disease Management|September 15, 2018
Identifying a new subtype of multiple sclerosisBruce D Trapp, Daniel OntanedaNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2016
Imaging as an Outcome Measure in Multiple SclerosisDaniel Ontaneda, Robert J FoxNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 4, 2017
The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical TrialsKedar R Mahajan, Daniel OntanedaCurrent Opinion in Neurology|April 19, 2015
Progressive multiple sclerosisDaniel Ontaneda, Robert J FoxPageof 41